Abstract
Background
Existing research exploring associations between atopic eczema (AE) or psoriasis, and severe mental illness (SMI – ie, schizophrenia, bipolar disorder, other psychoses) is limited, with longitudinal evidence particularly scarce. Therefore, temporal directions of associations are unclear. We aimed to investigate associations between AE or psoriasis and incident SMI among adults.
Methods
We conducted matched cohort studies using primary care electronic health records (January 1997 to January 2020) from the UK Clinical Practice Research Datalink GOLD. We identified two cohorts: 1) adults (≥18 years) with and without AE and 2) adults with and without psoriasis. We matched (on age, sex, general practice) adults with AE or psoriasis with up to five adults without. We used Cox regression, stratified by matched set, to estimate hazard ratios (HRs) comparing incident SMI among adults with and without AE or psoriasis.
Results
We identified 1,023,232 adults with AE and 4,908,059 without, and 363,210 with psoriasis and 1,801,875 without. After adjusting for matching variables (age, sex, general practice) and potential confounders (deprivation, calendar period) both AE and psoriasis were associated with at least a 17% increased hazard of SMI (AE: HR=1.17,95% CI=1.12–1.22; psoriasis: HR=1.26,95% CI=1.18–1.35). After additionally adjusting for potential mediators (comorbidity burden, harmful alcohol use, smoking status, body mass index, and, in AE only, sleep problems and high-dose glucocorticoids), associations with SMI did not persist for AE (HR=0.98,95% CI=0.93–1.04), and were attenuated for psoriasis (HR=1.14,95% CI=1.05–1.23).
Conclusion
Our findings suggest adults with AE or psoriasis are at increased risk of SMI compared to matched comparators. After adjusting for potential mediators, associations with SMI did not persist for AE, and were attenuated for psoriasis, suggesting that the increased risk may be explained by mediating factors (eg, sleep problems). Our research highlights the importance of monitoring mental health in adults with AE or psoriasis.
Keywords:
Abbreviations
AE, atopic eczema; BMI, body mass index; CI, confidence interval; CPRD, Clinical Practice Research Datalink, HR, hazard ratio; SMI, severe mental illness.
Declarations
This paper was presented at the Society for Academic Primary Care (SAPC) Annual Scientific Meeting (ASM) 2022 as a short oral presentation. The abstract for the talk can be found on the SAPC ASM 2022 website (doi: https://sapc.ac.uk/doi/10.37361/asm.2022.1.1). This study is based in part on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The data are provided by patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained in this study are those of the author/s alone.
Data Sharing Statement
Data may be obtained from a third party and are not publicly available. Data from this study were obtained from the Clinical Practice Research Datalink (CPRD) and to guarantee patient data confidentiality, only the authors have access to the data during the study, and the data cannot be distributed to other parties. Data are available directly from CPRD subject to independent approval.
Ethics Approvals and Patient Consent
This study was approved by the United Kingdom Clinical Practice Research Datalink (CPRD) Independent Scientific Advisory Committee (protocol 20_051) and London School of Hygiene and Tropical Medicine (LSHTM) Research Ethics Committee. This study was performed in line with the principles of the Declaration of Helsinki. Consent is given by GP practices that contribute to CPRD. Individual patient consent is implied. However, patients are offered the right to opt out from the use of their de-identified data.
Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
Disclosure
JFH has received consultancy fees from Wellcome Trust and juli Health. RM has received consulting fees from AMGEN. CS has received grants from Medical Research Council (MRC) and European Consortium (EC) funded consortia with multiple industry partners (see biomap-eu.im and PSORT.org.uk for details) and SML is also an investigator on BIOMAP but without industry funding and reports grants from Wellcome Trust; CS has received departmental research funding from AbbVie, Novartis, Pfizer, Sanofi, Boehringer Ingelheim, and SOBI. KM has received consultancy fees from AMGEN. The remaining authors declare that they have no relevant conflicts of interest.